The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin Cytotoxicity
Open accessAbstract
Rhes-olving Huntington's Disease?: Huntington's disease (HD) is caused by a single dominant mutation of huntingtin (Htt), a protein that occurs in all tissues of the body and that is uniformly distributed throughout the brain. How mutant Htt (mHtt) selectively damages striatal neurons with negligible alterations elsewhere has been a mystery. Subramaniam et al. (p. 1327 ) show that Rhes, a small G protein very highly localized to the striatum, binds mHtt and augments its neurotoxicity. Rhes promotes sumoylation of mHtt, leading to its disaggregation and augmented cytotoxicity. The findings establish how mHtt selectively kills cells in the striatum and suggest that Rhes-Htt binding might provide a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Concepts in sumoylation: a decade on
Geiss-Friedlander, R., & Melchior, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2293 · Cited by 1,785
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914
Hodgson, J. G., Agopyan, N., Gutekunst, C.-A., Leavitt, B. R., LePiane, F., Singaraja, R., Smith, D. J., Bissada, N., McCutcheon, K., Nasir, J., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80764-3 · Cited by 830
The Nucleoporin RanBP2 Has SUMO1 E3 Ligase Activity
Pichler, A., Gast, A., Seeler, J. S., Dejean, A., & Melchior, F. (2002) · Cell · doi:10.1016/s0092-8674(01)00633-x · Cited by 816
Schilling, G. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.3.397 · Cited by 753
SUMO Modification of Huntingtin and Huntington's Disease Pathology
Steffan, J. S., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L. C., Slepko, N., Illes, K., Lukacsovich, T., Zhu, Y.-Z., Cattaneo, E., et al. (2004) · Science · doi:10.1126/science.1092194 · Cited by 713
Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells
Trettel, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2799 · Cited by 610
Neurological abnormalities in a knock-in mouse model of Huntington's disease
Lin, C.-H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.2.137 · Cited by 592
Cited by
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders
Hardingham, G. E., & Bading, H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2911 · Cited by 1,644
The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition
Gareau, J. R., & Lima, C. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3011 · Cited by 1,105
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
Compromised autophagy and neurodegenerative diseases
Menzies, F. M., Fleming, A., & Rubinsztein, D. C. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3961 · Cited by 851
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Mechanisms, regulation and consequences of protein SUMOylation
Wilkinson, K. A., & Henley, J. M. (2010) · Biochemical Journal · doi:10.1042/bj20100158 · Cited by 686
Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders
Parsons, M. P., & Raymond, L. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.030 · Cited by 553
Hydrogen sulfide as a gasotransmitter
Gadalla, M. M., & Snyder, S. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06580.x · Cited by 498
Self-citationRepeat expansion disease: progress and puzzles in disease pathogenesis
La Spada, A. R., & Taylor, J. P. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2748 · Cited by 488
Okamoto, S.-I., Pouladi, M. A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D. E., Zaidi, R., Clemente, A., Kaul, M., Graham, R. K., et al. (2009) · Nature Medicine · doi:10.1038/nm.2056 · Cited by 436
Wong, Y. C., & Holzbaur, E. L. F. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1870-13.2014 · Cited by 398
Protein aggregates in Huntington's disease
Arrasate, M., & Finkbeiner, S. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.013 · Cited by 383
Huntington's disease: underlying molecular mechanisms and emerging concepts
Labbadia, J., & Morimoto, R. I. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.05.003 · Cited by 369
mTOR in Brain Physiology and Pathologies
Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 356
Chang, H.-M., & Yeh, E. T. H. (2020) · Physiological Reviews · doi:10.1152/physrev.00025.2019 · Cited by 355
Gu, X., Greiner, E. R., Mishra, R., Kodali, R., Osmand, A., Finkbeiner, S., Steffan, J. S., Thompson, L. M., Wetzel, R., & Yang, X. W. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.020 · Cited by 323
Finkbeiner, S. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007476 · Cited by 255
Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington’s disease
Plotkin, J. L., Day, M., Peterson, J. D., Xie, Z., Kress, G. J., Rafalovich, I., Kondapalli, J., Gertler, T. S., Flajolet, M., Greengard, P., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.032 · Cited by 187
Cyclic GMP-AMP synthase promotes the inflammatory and autophagy responses in Huntington disease
Sharma, M., Rajendrarao, S., Shahani, N., Ramírez-Jarquín, U. N., & Subramaniam, S. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2002144117 · Cited by 155
Self-citationHsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.
Gaughwin, P. M., Ciesla, M., Lahiri, N., Tabrizi, S. J., Brundin, P., & Björkqvist, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr111 · Cited by 145
Burke, K. A., Yates, E. A., & Legleiter, J. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00017 · Cited by 127
Mealer, R. G., Murray, A. J., Shahani, N., Subramaniam, S., & Snyder, S. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.536912 · Cited by 124
Self-citationGhose, J., Sinha, M., Das, E., Jana, N. R., & Bhattacharyya, N. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023837 · Cited by 98
Rhes travels from cell to cell and transports Huntington disease protein via TNT-like protrusion
Sharma, M., & Subramaniam, S. (2019) · Journal of Cell Biology · doi:10.1083/jcb.201807068 · Cited by 76
Self-citationThe striatal kinase DCLK3 produces neuroprotection against mutant huntingtin
Galvan, L., Francelle, L., Gaillard, M.-C., de Longprez, L., Carrillo-de Sauvage, M.-A., Liot, G., Cambon, K., Stimmer, L., Luccantoni, S., Flament, J., et al. (2018) · Brain · doi:10.1093/brain/awy057 · Cited by 47
“For example, dopamine and its subtype 2 membrane receptors (D2R), PDE10a, and the small GTPase Rhes have been shown to be preferentially expressed in the striatum, have early reduction of their expression in Huntington’s disease patients and Huntington’s disease models and have been shown to render striatal neurons hi…”
BackgroundLi, Y.-J., Du, L., Wang, J., Vega, R., Lee, T. D., Miao, Y., Aldana-Masangkay, G., Samuels, E. R., Li, B., Ouyang, S. X., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.026 · Cited by 50
Yu, X., Bian, X., Throop, A., Song, L., Moral, L. D., Park, J., Seiler, C., Fiacco, M., Steel, J., Hunter, P., et al. (2014) · Theranostics · doi:10.7150/thno.8255 · Cited by 34
Tunneling nanotubes: A novel pharmacological target for neurodegenerative diseases?
Wang, X.-T., Sun, H., Chen, N.-H., & Yuan, Y.-H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105541 · Cited by 22
Metadata
- Authors
- Subramaniam, S., Sixt, K. M., Barrow, R., & Snyder, S. H.
- Venue
- Science
- Published
- 2009-06-05
- Volume
- 324
- Issue
- 5932
- Pages
- 1327-1330
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2077886237
- Cited by
- 340
- References
- 30
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.